Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intervention to reduce the incidence of surgical site infection in spine surgery.
Castellà L, Sopena N, Rodriguez-Montserrat D, Alonso-Fernández S, Cavanilles JM, Iborra M, Ciercoles A, Pulido A, Gimenez M, Hernandez Hermoso JA, Casas I. Castellà L, et al. Among authors: iborra m. Am J Infect Control. 2020 May;48(5):550-554. doi: 10.1016/j.ajic.2019.09.007. Epub 2019 Nov 7. Am J Infect Control. 2020. PMID: 31706545 Free article. Clinical Trial.
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
Mínguez A, Coello E, Garrido A, Ripoll P, Gomez M, Aguas M, Iborra M, Cerrillo E, Tortosa L, Bayarri V, Bueno N, Fernández MJ, Marqués R, Nos P, Bastida G. Mínguez A, et al. Among authors: iborra m. Gastroenterol Hepatol. 2024 Sep 11:502253. doi: 10.1016/j.gastrohep.2024.502253. Online ahead of print. Gastroenterol Hepatol. 2024. PMID: 39270973 English, Spanish.
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial.
Ginard D, Barreiro-de Acosta M, Nos P, Moraleja I, Muñoz Nuñez F, Aldeguer X, Echarri A, Villoria A, Riestra S, Boscá Watts MM, González-Lama Y, Royo V, Ferreiro-Iglesias R, Iborra M, Elorza A, Fernandez-Pordomingo A, Sans M; Becalcu study. Ginard D, et al. Among authors: iborra m. Dig Dis. 2024 Aug 22:1-10. doi: 10.1159/000540792. Online ahead of print. Dig Dis. 2024. PMID: 39173598 Free article.
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
Iborra M, Caballol B, Garrido A, Huguet JM, Mesonero F, Ponferrada Á, Arias García L, Boscá Watts MM, Fernández Prada SJ, Brunet Mas E, Gutiérrez Casbas A, Cerrillo E, Ordás I, Ruiz L, García de la Filia I, Escobar Ortiz J, Sicilia B, Ricart E, Domènech E, Nos P. Iborra M, et al. J Crohns Colitis. 2024 Aug 22:jjae127. doi: 10.1093/ecco-jcc/jjae127. Online ahead of print. J Crohns Colitis. 2024. PMID: 39171615
HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.
Calafat M, Suria C, Mesonero F, de Francisco R, Caballero CY, Peña L, Hernández-Camba A, Marcé A, Gallego B, Martín-Vicente N, Rivero M, Iborra M, Guerra I, Carrillo-Palau M, Madero L, Burgueño B, Monfort D, Torres G, Teller M, Ferrer Rosique JÁ, Villaamil PV, Roig C, Ponferrada-Diaz A, Glaría EB, Zabana Y, Gisbert JP, Busquets D, Alcaide N, Camps B, Legido J, González-Vivo M, Bosca-Watts MM, Pérez-Martínez I, Deza DC, Guardiola J, Hernández LA, Navarro M, Gargallo-Puyuelo CJ, Cañete F, Mañosa M, Domènech E; ENEIDA registry of GETECCU. Calafat M, et al. Among authors: iborra m. Am J Gastroenterol. 2024 Jul 15. doi: 10.14309/ajg.0000000000002965. Online ahead of print. Am J Gastroenterol. 2024. PMID: 39008547
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Ferreiro-Iglesias R, Porto Silva S, Marín S, Casanova MJ, Mañosa M, González-Muñoza C, de Francisco R, Caballol B, Arias L, Piqueras M, Zabana Y, Rivero M, Calvet X, Mesonero F, Varela Trastoy P, Busta Nistal R, Gómez Perosanz R, Vega P, Gonzalez-Vivo M, Iborra M, Bermejo F, Madero L, Rodríguez-Lago I, Rodríguez Gonzalez M, Vera I, Ponferrada Díaz Á, Vela M, Torrealba Medina L, Van Domselaar M, Gomollón F, Iglesias E, Gisbert JP, Calafat M, Giordano A, Pérez-Martínez I, Ricart E, Sicilia B, Mena R, Esteve M, Rivas C, Brunet-Mas E, Fernández C, de Jorge Turrión MÁ, Velayos Jiménez B, Quiñones Calvo M, Regueiro Expósito C, Márquez-Mosquera L, Nos P, Granja A, Gutiérrez A, Cabriada JL, Hervías Cruz D, Calvo M, Pérez Pérez J, Rodríguez Díaz Y, Busquets Casal D, Menacho M, Leal C, Lucendo AJ, Royo V, Olivares S, Álvarez Herrero B, Carrillo-Palau M, Gilabert Álvarez P, Manceñido Marcos N, Martínez-Pérez TJ, Muñoz Villafranca MC, Almela P, Argüelles-Arias F, Legido J, Fuentes Coronel AM, Nieto L, Domènech E, Barreiro-de Acosta M; ENEIDA project sponsored by GETECCU. Ferreiro-Iglesias R, et al. Among authors: iborra m. Aliment Pharmacol Ther. 2024 Sep;60(5):604-612. doi: 10.1111/apt.18133. Epub 2024 Jun 28. Aliment Pharmacol Ther. 2024. PMID: 38943230
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
Sanz Segura P, Gomollón F, Casas D, Iborra M, Vela M, Fernández-Clotet A, Muñoz R, García de la Filia I, García Prada M, Ferrer Rosique JÁ, García MJ, de Francisco R, Arias L, Barrio J, Guerra I, Ponferrada Á, Gisbert JP, Carrillo-Palau M, Calvet X, Márquez-Mosquera L, Gros B, Cañete F, Monfort D, Madrigal Domínguez RE, Roncero Ó, Laredo V, Montoro M, Muñoz C, López-Cauce B, Lorente R, Fuentes Coronel A, Vega P, Martín D, Peña E, Varela P, Olivares S, Pajares R, Lucendo AJ, Sesé E, Botella Mateu B, Nos P, Domènech E, García-López S; ENEIDA project of GETECCU. Sanz Segura P, et al. Among authors: iborra m. Dig Liver Dis. 2024 Dec;56(12):2060-2068. doi: 10.1016/j.dld.2024.05.021. Epub 2024 Jun 13. Dig Liver Dis. 2024. PMID: 38876834
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
Gómez-Labrador C, Ricart E, Iborra M, Iglesias E, Martín-Arranz MD, de Castro L, De Francisco R, García-Alonso FJ, Sanahuja A, Gargallo-Puyuelo CJ, Mesonero F, Casanova MJ, Mañosa M, Rivero M, Calvo M, Sierra-Ausin M, González-Muñoza C, Calvet X, García-López S, Guardiola J, Arias García L, Márquez-Mosquera L, Gutiérrez A, Zabana Y, Navarro-Llavat M, Lorente Poyatos R, Piqueras M, Torrealba L, Bermejo F, Ponferrada-Díaz Á, Pérez-Calle JL, Barreiro-de Acosta M, Tejido C, Cabriada JL, Marín-Jiménez I, Roncero Ó, Ber Y, Fernández-Salazar L, Camps Aler B, Lucendo AJ, Llaó J, Bujanda L, Muñoz Villafranca C, Domènech E, Chaparro M, Gisbert JP. Gómez-Labrador C, et al. Among authors: iborra m. Pharmaceutics. 2024 May 8;16(5):629. doi: 10.3390/pharmaceutics16050629. Pharmaceutics. 2024. PMID: 38794292 Free PMC article.
132 results